

DAFTAR PUSTAKA

1. Wen M, Li Z, Li J et al. Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers. *Blood Purif.* 2019; 1-7.
2. Liyanage T, Ninomiya T, Jha V, et al. Worldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review. *Lancet.* 2015;385(9981):1975-1982.
3. *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.* Vol.3; 2013.
4. Suwitra K. Penyakit Ginjal Kronik. In: Sudoyo AW, Setiyohadi, et al. *Buku Ajar Ilmu Penyakit Dalam jilid II.* Jakarta, Indonesia: Interna Publishing. 2014: 2159-2165.
5. Zhou C, Shi Z, Ouyang N, et al. Hyperphosphatemia and Cardiovascular Disease. *Front Cell Dev Biol.* 2021;9:1-11.
6. Gutiérrez OM. The Connection between Dietary Phosphorus, Cardiovascular Disease, and Mortality: Where we stand and what we need to know. *Adv Nutr.* 2013;4(6):723-729.
7. Chang AR, Anderson C. Dietary Phosphorus Intake and the Kidney. *Annu Rev Nutr.* 2017;37:1-26.
8. Toussaint ND, Pedagogos E, Tan SJ, et al. Phosphate in Early Chronic Kidney Disease: Associations with Clinical Outcomes and A Target to Reduce Cardiovascular Risk. *Nephrology.* 2012;17(5):433-444.
9. Van Der Vaart A, Yeung SMH, Van Dijk PR, et al. Phosphate and Fibroblast Growth Factor 23 in Diabetes. *Clin Sci.* 2021;135(14):1669.
10. Hruska KA, Seifert M, Sugatani T. Pathophysiology of the Chronic Kidney Disease - Mineral Bone Disorder. *Curr Opin Nephrology Hypertens.* 2015;24(4):303-309.
11. Sprague SM, Martin KJ, Coyne DW. Phosphate Balance and CKD–Mineral Bone Disease. *Kidney Int Rep.* 2021;6(8):2049-2058.
12. Hoar S, Morton AR, Meers C, et al. A Multidisciplinary Approach to The Control of Calcium x Phosphate Product in. *Dial Transplant.* 1999;28: 309-313.
13. Cozzolino M, Dusso AS, Slatopolsky E. Role of Calcium-Phosphate Product and Bone Associated Proteins on Vascular Calcification in Renal Failure. *J Am Soc Nephrology.* 2001; 12: 2511-2516.
14. Neill WC. The Fallacy of The Calcium-Phosphorus Product. *Int Society of Nephrology.* 2007;72:792-796.

15. Jung DH, Park B, Lee YJ. Longitudinal Effects of Serum Calcium and Phosphate Levels and Their Ratio on Incident Ischemic Heart Disease among Korean Adults. *Biomolecules*. 2022;12(103):2-11.
16. Ganesh SK, Stack AG, Levin NW, et al. Association of Elevated Serum PO_4 , $\text{Ca} \times \text{PO}_4$ Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. *J Am Soc Nephrology*. 2001;12:2131-2138.
17. Block GA, Shearon TE, Levin NW, et al. Association of Serum Phosphorus and Calcium X Phosphate Product With Mortality Risk in Chronic Hemodialysis Patients: A National Study. *Am J Kidney Dis*. 1998;31(4):607-617.
18. Yasin A, Liu D, Chau L, et al. Fibroblast Growth Factor-23 and Calcium Phosphate Product in Young Chronic Kidney Disease Patients: A Cross-Sectional Study. *BMC Nephrology*. 2013;14(39):1-8.
19. Menon V, Greene T, Pereira AA, et al. Relationship of Phosphorus and Calcium-Phosphorus Product With Mortality in CKD. *Am J Kidney Dis*. 2005;46(3):455-463.
20. Slawuta P, Kumiega E, Kopylowics AS, et al. An Attempt to use The Serum Concentration of the Phosphate (P_i) and the $\text{Ca} \times \text{P}$ Product As Markers of the Progression of Chronic Kidney Disease. *Polish J Veterinary Sci*. 2019;22(4):647-652.
21. Lederer E. Regulation of Serum Phosphate. *J Physiol*. 2014;592(18):3985-3995.
22. Vervloet MG, Sezer S, Massy ZA, et al. The Role of Phosphate in Kidney Disease. *Nature Rev Nephrology*. 2017;13:27-38.
23. Guyton CA, Hall JE. Textbook of Medical Physiology: Pembentukan Urin oleh Ginjal Ed. 11. Jakarta: EGC; 2007. 331-333.
24. Rastogi A, et al. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. *J Renal Nutr*. 2021;31(1):21-34.
25. McCullough PA. Phosphate control: The Next Frontier in Dialysis Cardiovascular Mortality. *Cardio Renal Med*. 2021;11(3):123-132.
26. Fouque D, Vervloet M, Ketteler M. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease. *Nephrology*. 2018;78:1171-1186.
27. Barreto FC, Barreto DV, Massy ZA, et al. Strategies for Phosphate Control in Patients With CKD. *Kidney Int Rep*. 2019;4:1043-1056.
28. Deger SM, Mutluay R, Derici U, et al. Can Calcium, Phosphate, Calcium Phosphate Product and Intact Parathyroid Hormone Levels be Appropriately Controlled in Dialysis Patients?. *Med Princ Pract*. 2011; 20:

85-89.

29. *KDIGO 2003 Clinical Practice Guideline for Bone Metabolism and Disease in Chronic Kidney Disease*. Vol.42; 2003.
30. Movili E, Feliciani A, Camerini C, et al. A High Calcium-Phosphate Product is Associated with High C-Reactive Protein Concentrations in Hemodialysis Patients. *Nephrology Clin Pract*. 2005;101:161-67.
31. Vogt I, Haffner D, Nestler ML. FGF23 and Phosphate-Cardiovascular Toxins in CKD. *Toxins*. 2019;11:3-23.
32. Locatelli F, Andia JBC, Drueke TB, et al. Management of Disturbance of Calcium and Phosphate Metabolism in Chronic Renal Insufficiency, with Emphasis on The Control of Hyperphosphatemia. *Nephrology Dial Transplant*.2002;17:723-731.
33. Anser F, Dhrolia M, Nasir K. Corelation between Calcium-Phosphorus Product and Hypertension in End Stage Renal Disease Patient. *Cureus*. 2021;13(10):6-8.
34. Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patient Chronic. *Saudi Pharmac J*. 2014;1-34.
35. Keith AH, Mathew S, Lund R. Hyperphosphatemia of Chronic Kidney Disease. *Kidney Int*. 2008;74:148-157.
36. Distabanchong S. Vascular Calcification in Chornic Kidney Disease: Pathogenesis and Clinical Implication. *World J Nephrology*. 2012;1(2): 43-53.
37. Cozzolino M, Ciceri P, Galassi A, et al. The Key Role of Phosphate on Vascular Calcification. *Toxins (Basel)*. 2019;11(4):1-13.
38. Oliveira RB, Drueke TB, Stinghen A, et al. Vascular Calcification in Chronic Kidney Disease. *J Bras Nefrology*. 2013;35(2):147-161.
39. Tabibzadeh N, Mentaverri R, Daroux M, et al. Differential Determinants of Tubular Phosphate Reabsorption: Insights on Renal Excretion of Phosphates in Kidney Disease. *Am J Nephrology*. 2018;47(5):300-303.
40. Nadin C. Sevelamer as a Phosphate Binder in Adult Hemodialysis Patients: An Evidence-Based Review of Its Therapeutic Value. *Core Evid*. 2005;1(1):43-63.
41. Ting IW, Yeh HC, Huang HC, et al. Joint Longitudinal Low Calcium High Phosphorus Trajectory Associates with Accelerated Progression, Acute Coronary Syndrome and Mortality in Chronic Kidney Disease. *Sci Rep*. 2020;10:1-32.
42. Isakova T, Wahl P, Vargas GS, et al. Fibroblast Growth Factor 23 is Elevated Before Parathyroid Hormone and Phosphate in Chronic Kidney Disease. *Kidney Int*. 2011;79(12):1370-1378.
43. Cozzolino M, Bruschetta E, Cusi D, et al. Phosphate Handling in CKD-MBD from Stage 3 to Dialysis and The Three Strengths of Lanthanum Carbonate. *Expert Opin Pharmacother*. 2012;13(16):2337-2353.
44. Hioki H, Miyashita Y, Shiraki T, et al. Impact of Deteriorated Calcium-

Phosphate Homeostasis on Amputation-Free Survival After Endovascular Revascularization in Patients with Critical Limb Ischemia on Hemodialysis. *Vasc Med.* 2016;21(2):137-143.

45. Rogers M, Goettsch C, Aikawa E. Medial Intimal Calcification in Chronic Kidney Disease : Stressing the Contributions. *J Am Heart Assoc.* 2013;2: 1-7.



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431




Keputusan Protokol Amandemen
 No.76/UN4.6.4.5.31/PP36/2022

Nomor Protokol : UH20110690

Judul Protokol :		Hubungan Laju Filtrasi Glomerulus dan Kadar Kalsium-Fosfat Produk Pada Penyakit Ginjal Kronik				
Nama Peneliti	: dr. Rizki Primasari					
Institusi	: Interna					
Review Protokol Amandemen Ya <input checked="" type="checkbox"/> Tidak <input type="checkbox"/>	Tanggal review sebelumnya 31 Mei 2021					
Keputusan	<input checked="" type="checkbox"/> Disetujui <input type="checkbox"/> Disetujui dengan Modifikasi amandemen dan informed consent <input type="checkbox"/> Dihentikan, sambil menunggu informasi lanjut (3) <input type="checkbox"/> Butuh informasi lanjut, tetap berjalan dengan protokol sebelumnya (4) <input type="checkbox"/> Ditolak, bisa lanjut dengan persetujuan sebelumnya (5)					
Tempat Penelitian :	RS Dr. Wahidin Sudirohusodo Makassar					
No. Versi Protokol	02					
No. Versi Informed Consent	02					
No.	Nama Reviewer	Keputusan				
		1	2	3	4	5
1		<input checked="" type="checkbox"/>				


Makassar, 15 Pebruari 2022

Ketua


 Prof. Dr. dr. Suryani As'ad, M.Sc, Sp.GK. (K)
 NIP 19600504 1986 01 2 002



Sekretaris


 dr. Agussalim Bukhari, M.Med, PhD Sp.GK(K)
 NIP 197008021 1999 03 1 001

